Pruritis Clinical Trial
Official title:
Relieving Chronic Itch : Oral Medication
This study evaluates the effect of twice daily dose of INCB39110 in the treatment of itch in adults.
Chronic idiopathic itch accompanies low-grade skin inflammation. These inflammatory features are associated with cytokine production which signal through the common JAK1-STAT pathway. It is therefore theorized that a selective JAK1 inhibitor such as INCB039110 may provide relief of itch symptom. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04518618 -
Effect of Intrathecal Naloxone in the Incidence of Pruritis After C.S
|
N/A | |
| Completed |
NCT00693654 -
Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
|
Phase 4 | |
| Completed |
NCT00323154 -
Nalbuphine for the Treatment of Opioid Induced Pruritus in Children
|
Phase 3 | |
| Completed |
NCT03816891 -
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
|
Phase 2 | |
| Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
| Completed |
NCT01114672 -
A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06226610 -
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
|
Phase 2 |